Globally, annual spending on anticancer drugs is around US $100 billion, and is predicted
to rise to $150 billion by 2020. In the USA, a novel anticancer drug routinely costs more than …

The high prices of brand-name prescription drugs are a growing source of controversy in the
United States. Manufacturers of brand-name drugs can command high prices because they …

Cancer care in the United States remained a mixed picture in 2015. Declining mortality
rates, growing numbers of survivors, and exciting progress in treatment were set against the …

There are widespread claims that a productivity crisis afflicts the US pharmaceutical industry
despite the fact that the US institutional environment provides unique advantages for drug …

Institutional payers for pharmaceuticals worldwide appear to be increasingly negotiating
confidential discounts off of the official list price of pharmaceuticals purchased in the …

Importance Physicians from many specialties as well as primary care prescribe dermatologic
medications; as insurance formularies become increasingly restrictive and more patients are …

Keeping the economy strong will require addressing two distinct but related problems.
Steadily rising federal debt makes it harder to grow our economy, boost our living standards …

Corruption in healthcare generally and specifically in the pharmaceutical arena has recently
been highlighted in reports by Transparency International. This article focuses on four areas …

This American College of Physicians position paper, initiated and written by its Health and
Public Policy Committee and approved by the Board of Regents on 16 February 2016 …

The boundaries of what constitutes “sufficient” health have always been open and, as such,
health care has proven to be an opportune area for profit growth. In the United States, the …